Chonluten (Glu-Asp-Gly): Ultrashort Peptide Bioregulation, LPS-Responsive Monocyte Signaling, and Bronchial Research Context
Abstract Chonluten is a synthetic ultrashort tripeptide generally designated EDG, corresponding to the sequence GluAspGly. It belongs to the Khavinson peptidebioregulator research tradition and is described as bronchial or respiratorysystem oriented. The direct Chonlutenspecific peerreviewed evidence remains limited, with the strongest accessible dataset arising from a human THP1 monocyte/macrophage invitro model rather than a respiratory tissue or clinical study. In that system, the peptide was evaluated alongside other short bioregulatory peptides under basal and lipopolysaccharide (LPS)challenged conditions. The investigators reported modulation of inflammatory outputs, including attenuation of LPSstimulated TNF and IL6, phosphorylation of selected signaling proteins, and reduced monocyte adhesion to LPSactivated endothelial cells [1]. This article distinguishes direct evidence for EDG/Chonluten from classlevel transport hypotheses and from research on related bronchial peptides. In particular, the robust 2014 bronchialepithelium study frequently cited in discussions of this product tested the distinct tetrapeptide AlaAspGluLeu (ADEL), not EDG. Its findings must therefore not be represented as Chonluten data [2]. This review examines Chonluten’s molecular identity, its direct invitro immunomodulatory observations, the proposed but unconfirmed cellularaccess and epigeneticregulation framework for ultrashort peptides, and the limits that currently prevent clinical extrapolation. Molecular Identity and Research Lineage Sequence, Formula, and Physicochemical Character Chonluten is generally identified as the linear tripeptide GluAspGly, abbreviated EDG in oneletter residue notation. The reported molecular formula is C₁₁H₁₇N₃O₈, and the molecular weight is approximately 319.27 g/mol. Its sequence incorporates two acidic amino acids, glutamic acid and aspartic acid, followed by glycine. At physiological pH, the two acidic side chains are expected to contribute negative charge, whereas the free Nterminus and Cterminus contribute additional ionizable groups. This compact, acidic architecture is materially different from longer receptoractive peptide therapeutics: it offers few residues for a conventional receptorbinding epitope and is instead discussed within an ultrashortpeptide signaling framework. Ultrashort peptides are commonly defined as compounds containing approximately two to seven aminoacid residues. In the general transport literature, dipeptides and tripeptides can serve as substrates for protoncoupled oligopeptide transporters such as PEPT1 and PEPT2, while the ability of individual ultrashort sequences to use a given carrier varies with chemical structure. Reviews of POT and LAT carrier biology provide a plausible route by which short peptides may access cells in multiple tissues, including the lung, but they do not establish Chonlutenspecific uptake, intracellular exposure, or a clinical pharmacokinetic profile [3]. The Bronchial Bioregulator Concept Chonluten is described in the peerreviewed Khavinson bioregulator literature as a synthetic bronchial tripeptide with the respiratory system as its principal intended biological context [1]. The historical model is that peptides originally characterized from tissuederived peptide fractions can be simplified into short synthetic sequences that retain some tissueassociated regulatory behavior. This proposed organ specificity remains a research hypothesis rather than a clinically established targeting mechanism. It should not be interpreted as proof that systemically administered EDG selectively accumulates in human airway epithelium. An Essential Nomenclature Distinction: Chonluten Is Not ADEL A major evidenceinterpretation issue concerns the related bronchial tetrapeptide AlaAspGluLeu (ADEL), which is frequently discussed in the same research ecosystem. Khavinson and colleagues reported that ADEL altered proliferation and differentiationassociated markers in human embryonic bronchial epithelial cultures, including Ki67, Mcl1, NOS3, NKX21, SCGB1A1, SCGB3A2, FOXA1, FOXA2, MUC4, MUC5AC, and SFTPA1 [2]. However, ADEL is a fourresidue peptide with a different sequence and should not be conflated with EDG. These results offer context for bronchial peptide research but do not validate identical mechanisms, gene targets, efficacy, or safety for Chonluten. Proposed Mechanistic Framework Cellular Access: TransporterBased Plausibility, Not Established Pharmacology Short peptide transport is an active area of pharmacology because PEPTfamily transporters recognize a wide range of di and tripeptides, including zwitterionic, cationic, and anionic sequences. PEPT2 is expressed in multiple organs, including the lung, while other SLC15 family members have distinct tissue distributions [3]. For EDG, this provides a biologically credible route for experimental investigation, but it remains an inference. No accessible Chonlutenspecific study has defined PEPT1 or PEPT2 affi
For research use only. Not for human consumption.